The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet need, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Cancer chimeric antigen receptor (CAR) T-cell therapy.
According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 areas of innovation that will shape the future of the industry.
Cancer chimeric antigen receptor (CAR) T-cell therapy is a key innovation area in immuno-oncology
CAR T-cell therapy utilises T-cells, which are engineered to express a chimeric antigen receptor which recognises and binds to an antigen on cancer cells targeting it for T-cell killing.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 250+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of cancer CAR T-cell therapy.
Key players in cancer chimeric antigen receptor (CAR) T-cell therapy – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to cancer chimeric antigen receptor (CAR) T-cell therapy
|Company||Total patents (2010 - 2021)||Premium intelligence on the world's largest companies|
|Immatics||2270||Unlock company profile|
|GSK||1114||Unlock company profile|
|Pfizer||482||Unlock company profile|
|OncoTherapy Science||437||Unlock company profile|
|Johnson & Johnson||301||Unlock company profile|
|BioNTech||181||Unlock company profile|
|Memorial Sloan Kettering Cancer Center||173||Unlock company profile|
|Bristol-Myers Squibb||151||Unlock company profile|
|CareGroup||146||Unlock company profile|
|Gilead Sciences||128||Unlock company profile|
|Centre National de la Recherche Scientifique||128||Unlock company profile|
|Inovio Pharmaceuticals||118||Unlock company profile|
|Merck & Co||104||Unlock company profile|
|SEEK Group||96||Unlock company profile|
|C. H. Boehringer Sohn||87||Unlock company profile|
|Curevac||82||Unlock company profile|
|US Department of Health and Human Services||82||Unlock company profile|
|AECOM||81||Unlock company profile|
|United States Of America||79||Unlock company profile|
|Otsuka Holdings||75||Unlock company profile|
|Esteve Pharmaceuticals||74||Unlock company profile|
|Autolus||71||Unlock company profile|
|Innovative Cellular Therapeutics||71||Unlock company profile|
|International AIDS Vaccine Initiative||71||Unlock company profile|
|Mitsubishi Chemical Group||69||Unlock company profile|
|Aleta Biotherapeutics||69||Unlock company profile|
|bluebird bio||68||Unlock company profile|
|Sumitomo Chemical||63||Unlock company profile|
|AGC||63||Unlock company profile|
|U.S. Department of Defense||63||Unlock company profile|
|ImmunityBio||62||Unlock company profile|
|TRON gGmbH||62||Unlock company profile|
|CRISPR Therapeutics||61||Unlock company profile|
|Sanofi||58||Unlock company profile|
|Fundacion IrsiCaixa||58||Unlock company profile|
|Fred Hutchinson Cancer Research Center||57||Unlock company profile|
|Altimmune||56||Unlock company profile|
|Solon Eiendom||50||Unlock company profile|
|Mymetics||48||Unlock company profile|
|Children's Medical Center||47||Unlock company profile|
|Novavax||45||Unlock company profile|
|Takeda Pharmaceutical||44||Unlock company profile|
|Novartis||44||Unlock company profile|
|Nestle||44||Unlock company profile|
|Scancell Holdings||43||Unlock company profile|
|Etubics||43||Unlock company profile|
|TCR2 Therapeutics||42||Unlock company profile|
|TheVax Genetics Vaccine||42||Unlock company profile|
|Mount Sinai Health System||41||Unlock company profile|
|Miltenyi Biotec||40||Unlock company profile|
Source: GlobalData Patent Analytics
Bristol-Myers Squibb (BMS) is one of the leading patent filers in the cancer CAR T-cell therapy market. The company recently entered a licensing agreement with Autolus Therapeutics and a CO-development agreement with Immatics for the development of CAR T-cell therapeutics. BMS has two approved CAR T-cell therapies. It received approval from the Ministry of Health, Labour and Welfare (MHLW) of Japan for its CAR T-cell therapy Abecma (idecabtagene vicleucel) to treat relapsed or refractory (R/R) multiple myeloma in adults and Breyanzi from the US Food and Drug Administration (FDA) for R/R large B-cell lymphoma. Furthermore, with Next-generation CAR T candidate known as Nex-T, BMS is incorporating a new manufacturing process that may reduce costs and provide faster production, as well as new CAR engineering for improved functionality.
Another leading filer is Gilead Sciences, which develops CAR T-cell therapy for cancer treatment. Gilead Sciences has two approved CAR T-cell therapies including Yescarta, which was first approved by the FDA in 2017. Kite, a Gilead Company, recently entered a licensing agreement with Refuge Biotechnologies to utilise Refuge’s proprietary gene expression platform to develop CAR T therapy for blood cancers. Kite also received FDA approval for the company's retroviral vector (RVV) manufacturing facility in Oceanside, California, US, for commercial production.
In terms of application diversity, Scancell Holdings Plc is the top company followed by GSK plc and C. H. Boehringer Sohn AG & CO KG. By geographic reach, Otsuka Holdings CO Ltd holds the top position. Inovio Pharmaceuticals Inc and OncoTherapy Science Inc are in the second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Immuno-Oncology – Thematic Research.